Follow
Cervical screening
Cervical screening is a test to screen for cervical cancers. New cervical screening test procedures are similar to a Pap smear test. For both tests a doctor or nurse takes a sample of cells from the cervix. However, the Pap smear test used to look for abnormal cells in the cervix, while the cervical screening test looks for HPV infection.
NOV 09, 2022 | 3:00 AM
Date: November 9, 2021 Time: 3:00am (PDT), 6:00am (EDT), 12:00pm (CEST) An increasing number of cervical cancer screening programs are converting from cytology to primary HPV-based organiz...
AUG 31, 2022 | 12:00 PM
Date: August 31, 2022 Time: 12:00pm (PDT), 3:00pm (EDT), 9:00pm (CEST) Human papillomavirus (HPV) is responsible for more than 99% of cervical cancers. Most HPV infections are transient an...
AUG 16, 2022 | 7:00 AM
Date: August 16, 2022 Time: 7:00am (PDT), 10:00am (EDT), 4:00pm (CEST) In this session, researchers, clinicians, and program implementers from four countries will address the disruption in co...
FEB 23, 2022 | 11:55 PM
Cancer is a leading cause of morbidity and mortality in developed countries including the United States. Early detection of various cancers, before they spread and become incurable, has been...
SEP 02, 2021 | 11:00 AM
La infección por el virus del papiloma humano (VPH) es el causante principal de cáncer de cuello uterino. Los tipos 16 y 18 del VPH son responsables...
JUN 17, 2021 | 11:00 AM
Date: June 17, 2021 Time: 11:00am PDT, 8:00pm CET BACKGROUND Kidney transplant recipients and patients on hemodialysis are immunocompromised populations excluded from vaccine trials. Data ar...
APR 21, 2021 | 12:00 AM
According to the American Cancer Society, in there were an estimated 110,070 new cases diagnosed and approximately 32,120 deaths from gynecologic cancers in the U.S. in 2018. Of the five mos...
OCT 07, 2020 | 9:00 AM
Date: October 7, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Recently the FDA approved the BD Onclarity HPV assay as a test to identify HPV high-risk genotypes in addition to HPV 16 and 18 i.e.,...
AUG 18, 2020 | 6:00 AM
DATE: August 18, 2020 TIME: 6:00am PDT, 9:00pm EDT Hundreds of HPV tests with different variants are commercially available globally, but many of these tests do not meet the performance char...
APR 29, 2020 | 6:00 AM
Background and aim: Multiplexing of biomarker panels by microsphere-based technologies are robust and cost-effective methods. The QuantiGene™ Plex Assay (ThermoFisher Scientific) platf...
JAN 30, 2020 | 9:00 AM
DATE: January 30, 2020 TIME: 9:00am PST, 12:00pm EST Recent advances in in vitro 3D cellular culture technologies, such as organoids, rapidly developed and established novel, more physiologi...
MAY 08, 2019 | 9:00 AM
DATE: May 8, 2019TIME: 12:00am PDT In 2017 the first national cervical screening programs using human papillomavirus (HPV-based) primary screening were implemented. As these progr...
NOV 15, 2018 | 10:30 AM
Cervical cancer is the 4th most common cancer worldwide with 528,000 new cases and 266,000 deaths every year. It is also the only cancer 100% preventable. It has been extensively proved, that...
NOV 15, 2018 | 10:30 AM
The main problem for insufficient cervical cancer screening globally (less than 20% women at risk) is outreach failure. Enabling POCs with modern IT/mobile technology and connecting them with...
